ABSTRACT Whereas insulin does not stimulate hexose transport in polymorphonuclear leukocytes, we recently reported that C5a causes the leukocytes to take up 243Hldeoxy-glucose. We now find that fMet-Leu-Phe, in a concentrationrelated manner with an ECso (concentration producing 50% of stimulatory activity) of 1.2 nM, causes a 5.5-fold stimulation of deoxyglucose uptake. Moreover, arachidonic acid (5, 8, 11, acid) similarly stimulated deoxyglucose uptake with an EC50 of 0.6 gM. Stimulation by arachidonic acid exhibited structural specificity; five structural analogues of arachidonic acid, including arachidonyl alcohol, 8,11,14-eicosatrienoic acid, 11,14,17-eicosatrienoic acid, 5,8,11,14- Substances originally defined as stimulating chemotaxis of human polymorphonuclear leukocytes (PMNL), such as C5a and the synthetic oligopeptide N-formylmethionylleucylphenylalanine (fMet-Leu-Phe), interact with specific membrane receptors (1-3) that induce multifunctional cellular responses. In addition to stimulating motility, such chemotactic factors also stimulate adhesiveness (4, 5), aggregation (5-7), degranulation (3, 8) , and oxidative metabolism (9-12) of PMNL. PMNL require energy derived from glucose for each of these functions. It would be reasonable if chemotactic substances interacted with hexose transport systems of the PMNL membrane to facilitate the availability of glucose. We recently reported that C5a stimulated the uptake of 2-[3H]deoxyglucose (dGlc) (13) . Similar concentrations of C5a were required to cause stimulation of chemotaxis and dGlc uptake. Whereas insulin had no effect on dGlc transport in PMNL, the 3-to 7-fold increase in uptake induced by C5a was comparable to that produced by insulin in human adipose tissue (14) .
ABSTRACT Whereas insulin does not stimulate hexose transport in polymorphonuclear leukocytes, we recently reported that C5a causes the leukocytes to take up 243Hldeoxy-glucose. We now find that fMet-Leu-Phe, in a concentrationrelated manner with an ECso (concentration producing 50% of stimulatory activity) of 1.2 nM, causes a 5.5-fold stimulation of deoxyglucose uptake. Moreover, arachidonic acid (5,8,11,14-eicosatetraenoic acid) similarly stimulated deoxyglucose uptake with an EC50 of 0.6 gM. Stimulation by arachidonic acid exhibited structural specificity; five structural analogues of arachidonic acid, including arachidonyl alcohol, 8 ,11,14-eicosatrienoic acid, 11,14,17-eicosatrienoic acid, 5, 8, 11, 14 -eicosatetraynoic acid, and arachidic acid, did not stimulate deoxyglucose uptake. Release and metabolism of arachidonic acid may also be involved in the stimulation of deoxyglucose uptake by fMet-Leu-Phe. Inhibitors of arachidonic acid metabolism (5,8,11,14-eicosatetraynoic acid, nordihydroguaiaretic acid, indomethacin, aspirin, and benzylimidazole) caused parallel changes in the responses to both arachidonic acid and fMetLeu-Phe. Stimulation of deoxyglucose uptake of lymorphonuclear leukocytes by chemotactic factors or aracidonic acid had the characteristics of carrier-facilitated hexose transport. The response was saturable with increasing concentrations of stimulant or substrate (deoxy lucose). It was stereospecific (inhibited by D-glucose but not by L-glucose) and was inhibited in resting and stimulated cells by 5 sg of cytochalasin Baper ml.
It was separable from the stimulation of oxidative metabolism; it occurred normally in polymorphonuclear leukocytes from a patient with chronic granulomatous disease (these are incapable of an oxidative metabolic response to membrane stimuli) Thus, stimulation of polymorphonuclear leukocytes is associated with enhanced hexose transport. Moreover, carrier-acilitated hexose transport and arachidonic acid metabolism may be linked, at least in these leukocytes: arachidonic acid mimics the stimulatory effects of chemotactic factors, and blockade of arachidonic acid metabolism inhibits the stimulation of hexose transport by these agents.
Substances originally defined as stimulating chemotaxis of human polymorphonuclear leukocytes (PMNL), such as C5a and the synthetic oligopeptide N-formylmethionylleucylphenylalanine (fMet-Leu-Phe), interact with specific membrane receptors (1-3) that induce multifunctional cellular responses. In addition to stimulating motility, such chemotactic factors also stimulate adhesiveness (4, 5) , aggregation (5-7), degranulation (3, 8) , and oxidative metabolism (9-12) of PMNL. PMNL require energy derived from glucose for each of these functions. It would be reasonable if chemotactic substances interacted with hexose transport systems of the PMNL membrane to facilitate the availability of glucose. We recently reported that C5a stimulated the uptake of 2-[3H]deoxyglucose (dGlc) (13) . Similar concentrations of C5a were required to cause stimulation of chemotaxis and dGlc uptake. Whereas insulin had no effect on dGlc transport in PMNL, the 3-to 7-fold increase in uptake induced by C5a was comparable to that produced by insulin in human adipose tissue (14) .
Stimulation of membrane receptors by chemotactic factors produces a number of membrane responses which have been suggested as a sequence culminating in stimulation of cellular functions (15) (16) (17) . These include (i) increase in levels of free calcium by influx of extracellular Ca2+ and (or) mobilization of intracellular or membrane-bound Ca2+ (18) (19) (20) (21) (22) , (ii) activation of calcium-dependent phospholipase A2 (23), (iM) release of arachidonic acid from membrane phospholipids (24) , and (iv) metabolism of arachidonic acid with generation of bioactive products (16, (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , some of which are reincorporated into the membrane (30, 31) possibly causing increased membrane fluidity. Whether these events are involved in the stimulation of hexose transport is unknown.
The synthetic oligopeptide fMet-Leu-Phe has been extensively used as an analogue of bacterical chemotactic factors and has proven invaluable as a probe for elucidating multifunctional effects and mechanisms of actions of chemotactic factors of PMNL. The present studies examined the ability of fMetLeu-Phe or arachidonic acid to stimulate dGlc uptake by PMNL, the effects of inhibitors of the cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism, and the nature of the hexose transport system. METHODS Preparation of PMNL. Heparinized blood was obtained from normal volunteers and from a patient with documented chronic granulomatous disease, and leukocyte-rich plasma was obtained by gravity sedimentation over Ficoll/diatrizoate (Isolymph; Gallard-Schlesinger, Carle Place, NY) as described (35) . Leukocytes were centrifuged at 150 X g for 8 min, resuspended in Dulbecco's phosphate-buffered saline, layered over Isolymph, and centrifuged at 400 X g for 10 min. The granulocyte pellet was resuspended and washed by centrifugation in phosphate-buffered saline. The final preparations contained >90% PMNL, the contaminating cells being eosinophils and lymphocytes. There were less than 2 platelets per 100 PMNL in the preparations.
Assay of Hexose Uptake.
[3H]dGlc (specific activity, 50 Ci/mol; 1 Ci = 3.7 X 1010 becquerels) (New England Nuclear) was diluted to 50 ,uCi/ml in H20 and stored at -20°C. As required, aliquots were further diluted to 5 ,uCi/ml with phosphate-buffered saline. Quadruplicate assays were performed in 1. phate-buffered saline/0.9 mM Ca2+/0.5 mM Mg2+. PMNL were preincubated for 15 min with substances to be tested (putative stimuli and inhibitors) at 370C in a shaking waterbath.
Uptake was initiated by addition of 0.5 of MCi [3H]dGlc (10 nmol , with a total activity of 388,000 cpm) and stopped after 60 min by addition of 1 ml of iced phosphate-buffered saline, and the samples were then centrifuged (Beckman Microfuge B) at 9000 X g for 20 sec. The pellets were washed with 1 ml of iced phosphate-buffered saline and recentrifuged. The supernatant was removed by aspiration, the pellet and tube were placed in scintillation vials containing 10 ml of Aquasol (New England Nuclear), and radioactivity was determined on a Beckman scintillation spectrometer (Beckman, Palo Alto, CA (36) . Aspirin (acetylsalicylic acid, Sigma) was prepared fresh before use and dissolved in buffer and the pH was immediately adjusted to 7.4.
Hexokinase Assay. PMNL were disrupted by sonication and centrifuged for 15 min at 27,000 X g at 4°C. Hexokinase activity in the supernate was determined by spectrophotometric assay. Reagents and putative inhibitors were dissolved in 50 mM triethanolamine.HCl buffer (pH 7.5). The reaction volume was 3 ml and contained 120 mg of glucose, 6.6 mM MgCl2, 2 mg of NADP, 1 mg of ATP, 1.25 units of purified glucose-6-phosphate dehydrogenase, and one of the following: no inhibitor, 30,uM ETYA, 10,uM NDGA, 100MtM indomethacin, or 5 mM aspirin.
The reaction was initiated by addition of 0.1 ml of PMNL sonicate (3.2 mg of protein per ml), and the increase in absorbance at 340 nm was measured on a Beckman DU Spectrophotometer with a Gilford recorder. Each measurement was performed in duplicate at two levels of protein.
Migration-Under-Agarose Assay. Stimulation of motility (chemokinesis) was examined by a modification of the migration-under-agarose assay reported previously (35) . Various concentrations of fMet-Leu-Phe were incorporated into the agarose so that the PMNL would be exposed to the full concentration of stimulant.
Statistical Analysis. Significance was examined by the unpaired Student t test.
RESULTS
Stimulation of Hexose Uptake by fMet-Leu-Phe. fMetLeu-Phe caused a 3-to 10-fold (mean, 5.5-fold) increase in the uptake of dGlc by human PMNL (Fig. 1) . The degree of stimulation was directly related to the concentration of fMetLeu-Phe, with an ECso (concentration producing 50% of stimulatory activity) of 1.2 nM. In the migration-under-agarose assay method, with incorporation of fMet-Leu-Phe into the agarose, this preparation of fMet-Leu-Phe causes stimulation of the motility of PMNL at an EC5o of 0.9 nM (data not shown). The nonformylated peptide Met-Leu-Phe required a concen- tration of 2MuM to stimulate dGlc uptake (Table 1) . Thus, similar relative concentrations of fMet-Leu-Phe and Met-Leu-Phe stimulate dGlc uptake and chemotaxis (8) .
Effect of Arachidonic Acid and Arachidonic Acid Analogues. Arachidonic acid caused a stimulation of hexose transport with an EC5o of 0.6 MM (Fig. 2) . Five structural analogues of arachidonic acid-ETYA (Fig. 2) , eicosanoic acid, 11,14,17-eicosatrienoic acid, 8,11,14-eicosatrienoic acid, and arachidonyl alcohol (Table 1 )-did not stimulate hexose uptake.
In preliminary experiments, we found that lymphocytes did not increase uptake of dGlc after stimulation with 10 nM (Fig. 1) or arachidonic acid (Fig. 2) . Because 2 nM fMet-Leu-Phe and 3 ,M arachidonic acid caused comparable stimulation of dGlc uptake, these stimuli were used in further studies of the effects of inhibitors of arachidonic acid metabolism (Fig. 3) . ETYA inhibits the formation and release of lipoxygenase-mediated arachidonic acid derivatives (monohydroxyeicosatetraenoic acids) by PMNL at an IC50 (concentration producing 50% inhibitory activity) of about 5-8AM (37, 38) ; ETYA was similarly potent in preventing the stimulation of dGlc uptake by 2 nM fMet-Leu-Phe and 3 MM arachidonic acid (ETYA IC50 values of 5.3 MM and 4.3 MM, respectively). NDGA, an inhibitor of lipoxygenase activity, blocks production of monohydroxyeicosatetraenoic acids by PMNL at an IC50 of about 3MM (37) ; NDGA inhibited the stimulation of dGlc uptake by fMet-Leu-Phe and arachidonic acid with IC50 values of 2.9 and 1.1 MuM, respectively. Thus, similar concentrations of ETYA and NDGA inhibited the effects of fMet-Leu-Phe and arachidonic acid on dGlc uptake, and the inhibitory effects on hexose transport closely paralleled the reported effects of these agents on lipoxygenase-mediated arachidonic acid metabolism. ETYA and NDGA, at the concentrations used, were not toxic to cells, as judged by trypan blue exclusion, lack of release of lactate dehydrogenase, and maintenance of a normal rate of dGlc uptake. Indomethacin (10 MM) and aspirin (5 mM), at concentrations that inhibit cyclooxygenase, did not inhibit stimulation of hexose transport (Fig. 3) . At higher concentrations (ICso values with fMet-Leu-Phe and arachidonic acid of 39 and 60MM, respectively), indomethacin inhibited dGlc uptake. Benzylimidazole inhibits thromboxane synthetase of platelets at concentrations below 1 ALM (39) . Such concentrations of benzylimidazole did not alter dGlc uptake of PMNL (Fig. 3) ; however, at 1000-fold higher levels (with EC50 values of 1.7 mM for fMet-Leu-Phe and 1.2 mM for arachidonic acid), this agent was inhibitory.
The use of dGlc to assess hexose transport is dependent upon the nearly irreversible phosphorylation of dGlc within the cells (40) . For the assay to be valid, inhibitors of transport must be shown not to inhibit hexokinase activity. ETYA (30MM), NDGA (10 ,M), indomethacin (100,MM), and aspirin (5 mM) had no effect on PMNL hexokinase (data not shown).
Nature (40) . Less than 8% of the tracer was sequestered within the cells. Thus, this procedure provides a valid estimate of enhancement of dGlc uptake by PMNL.
Substances that inhibit carrier-facilitated hexose transport in other systems similarly inhibited the uptake of dGlc. The uptake was completely inhibited by 10 mM D-glucose but was unchanged by 10 mM L-glucose (Table 2 ). Cytochalasin B (5 ,ig/ml) inhibited dGlc transport by approximately 90% in resting cells and cells stimulated by fMet-Leu-Phe or arachidonic acid ( Table 2) .
Stimulation of dGlc uptake was not dependent upon stimulation of oxidative glucose metabolism. PMNL obtained from a patient with chronic granulomatous disease, known to be incapable of an oxidative metabolic response to membrane stimuli, demonstrated dGlc uptake by resting and stimulated cells equal to that of normal cells (data not shown).
DISCUSSION
Chemotactic factors stimulate uptake of [3H]dGlc by PMNL. As previously shown with stimulation by C5a (4), the present studies demonstrated that fMet-Leu-Phe enhanced dGlc transport in a concentration-related manner. Similar concentrations of fMet-Leu-Phe stimulated dGlc transport and motility.
dGlc was used as a measure of glucose transport because it enters cells at the same site as glucose by a specific, saturable mechanism with characteristics compatible with carrier-facilitated transport in other cell systems (42) . Such stimulation of carrier-facilitated transport of hexoses by insulin is characterized by being saturable, by being inhibited by D-glucose but not by L-glucose, and by inhibition by cytochalasin B (any residual uptake can be ascribed to passive diffusion) (14, 43) . The previous study suggested that dGlc uptake also involved carrier-facilitated diffusion in PMNL (4) . This was supported by the -observation that the uptake was saturable with kinetics compatible with such a transport mechanism. Certain of the present observations further support that hypothesis. Stimulation of hexose uptake in PMNL also demonstrated stereospecificity. Cytochalasin B enhances many responses of PMNL to chemotactic factors, including aggregation (5) (6) (7) 44) , degranulation (3, 8) , and oxidative metabolism (10) (11) (12) , yet, as reported for resting PMNL (36) , cytochalasin B markedly inhibited dGlc transport by resting and stimulated cells. The degree of inhibition (over 90%) by cytochalasin B is comparable to the inhibition of insulin-mediated stimulation of hexose transport in other cell systems (43) . The stimulation of dGlc transport was unrelated to the stimulation of oxidative metabolism of glucose, because it occurred normally in PMNL from a patient with chronic granulomatous disease. The combined data strongly support the concept that the observed uptake of dGlc was by carrier-facilitated transport.
Recent studies have revealed several events that may occur after stimulation of membrane receptors of PMNL and may be interrelated in the coupling of receptor stimulation to functional cellular responses. These include mobilization of calcium ions, activation of phospholipase, and release and metabolism of arachidonic acid. In separate studies, we have found that mobilization of divalent cations may be involved in the stimulation of hexose transport of PMNL. The present studies examined the possible role of arachidonic acid.
Although arachidonic acid does not precisely duplicate the effects of chemotactic factors [e.g., arachidonic acid is not chemotactic (32, 33) ], several of the responses of PMNL to chemotactic factors appear to involve the release and metabolism of arachidonic acid. fMet-Leu-Phe causes arachidonic acid release (24) . Arachidonic acid causes degranulation of rabbit PMNL (45) and aggregation of human PMNL (44) . Blockade of lipoxygenase-mediated arachidonic acid metabolism prevents these responses and the oxidative metabolic response of guinea pig PMNL to fMet-Leu-Phe (46) .
The present studies demonstrated that arachidonic acid also stimulates hexose transport. Arachidonic acid stimulated dGlc uptake in a concentration-related manner with a potency similar to that known to cause aggregation of human PMNL (44) . Stimulation of transport by arachidonic acid involved structural specificity. Whereas arachidonic acid (5,8,11,14-eicosatetraenoic acid) stimulated transport, 8,11,14-eicosatrienoic acid, 11,14,17-eicosatrienoic acid, 5,8,11,14-eicosatetraynoic acid (ETYA), eicosanoic acid, and arachidonyl alcohol had no stimulatory effect. Thus, minimal structural modifications (e.g., absence of the C-5 double bond or reduction of the terminal carboxyl group to an alcohol) completely abolished the activity of arachidonic acid. Similar structural specificity has been reported for the aggregation of human PMNL and degranulation of rabbit PMNL (44, 45) .
Beyond the clear finding that arachidonic acid stimulates dGlc uptake, these studies also suggest that arachidonic acid may be involved in the response to fMet-Leu-Phe because structurally dissimilar blockers of arachidonic acid metabolism had similar effects on the actions of arachidonic acid and fMet-Leu-Phe. Thus, ETYA and NDGA, at concentrations that block lipoxygenase-mediated arachidonic acid metabolism by PMNL (37, 38) , were similarly potent inhibitors of dGlc uptake induced by both stimuli. Indomethacin and aspirin, at concentrations that inhibit cyclooxygenase-mediated arachidonic acid metabolism by PMNL (26) , were inactive. Similarly, benzylimidazole, at concentrations that inhibit thromboxane formation by other tissues (39) , had no effect. It is tempting to conclude that the action of lipoxygenase on arachidonic acid [whether exogenous or released from membrane phospholipids during the response to fMet-Leu-Phe (24) ] is necessary for the stimulation of hexose transport. However, the inevitable possibility that these inhibitors with putative specificity might act by other mechanisms and the observation that higher concentrations of indomethacin and benzylimidazole inhibited dGlc uptake temper such a conclusion. For example, at lower concentrations, ETYA (<30 ,uM) inactivates both lipoxygenase and cyclooxygenase (47) (48) (49) (50) (51) (52) , NDGA (<20 ,uM) inhibits lipoxygenase (48, 53) , indomethacin (<30,M) and aspirin (<1 mM) inhibit cyclooxygenase (26, 47, 54) , and benzylimidazole (<1 ,uM) inhibits thromboxane synthetase (39) activities of various cell types. Yet at higher concentrations, many of these agents lose this specificity. For instance, at >50 ,uM, NDGA inhibits platelet (55) (60, 61) . Associations between arachidonic acid metabolism and hexose transport in diverse tissues are worthy of further study.
